BCLIBrainstorm Cell Therapeutics Inc.

BCLI Stock Price, Valuation & Chart | Brainstorm Cell Therapeutics Inc.

Compare

$1.250+0.07 (+5.93%)

At close · 02 Sept 2026, 07:59 pm

Sector: Healthcare Industry: Biotechnology BCLI intrinsic value BCLI calculated fair value vs price

Overview Financials Dividends Ratios

BCLI Historical price chart

BCLI Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization13.79M

PE Ratio-0.77

EPS-1.63

Trading Volume19.58K

Today's High/Low1.28/1.13

Dividend Yield0.00

52 Week High/Low1.69/0.46

Shares Outstanding11.03M

BCLI Financial Statement

BCLI Analyst ratings

BCLI Analysis & performance metrics

BCLI Company profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of…

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of…

BCLI Management team

Name

Position

Ibrahim Dagher M.D.

Executive Vice President & Chief Medical Officer

Mary Kay Turner

Senior Vice President of Patient Advocacy & Government Affairs

Daniel Offen Ph.D.

Chief Scientific Advisor

Hartoun Hartounian Ph.D.COO

Executive Vice President & Chief Operating Officer

Netta Blondheim-Shraga Ph.D.

Senior Vice President of Research and Development

Chaim LebovitsCEO

President & Chief Executive Officer

Uri YablonkaCTO

Executive Vice President, Chief Business Officer, Secretary & Director

Name

Position

Ibrahim Dagher M.D.

Executive Vice President & Chief Medical Officer

Mary Kay Turner

Senior Vice President of Patient Advocacy & Government Affairs

Daniel Offen Ph.D.

Chief Scientific Advisor

Hartoun Hartounian Ph.D.COO

Executive Vice President & Chief Operating Officer

Netta Blondheim-Shraga Ph.D.

Senior Vice President of Research and Development

Chaim LebovitsCEO

President & Chief Executive Officer

Uri YablonkaCTO

Executive Vice President, Chief Business Officer, Secretary & Director

Management Team

Ibrahim Dagher M.D.

Executive Vice President & Chief Medical Officer

Mary Kay Turner

Senior Vice President of Patient Advocacy & Government Affairs

Daniel Offen Ph.D.

Chief Scientific Advisor

Hartoun Hartounian Ph.D.COO

Executive Vice President & Chief Operating Officer

Netta Blondheim-Shraga Ph.D.

Senior Vice President of Research and Development

Chaim LebovitsCEO

President & Chief Executive Officer

Uri YablonkaCTO

Executive Vice President, Chief Business Officer, Secretary & Director

Management

Ibrahim Dagher M.D.

Executive Vice President & Chief Medical Officer

Mary Kay Turner

Senior Vice President of Patient Advocacy & Government Affairs

Daniel Offen Ph.D.

Chief Scientific Advisor

Hartoun Hartounian Ph.D.COO

Executive Vice President & Chief Operating Officer

Netta Blondheim-Shraga Ph.D.

Senior Vice President of Research and Development

Chaim LebovitsCEO

President & Chief Executive Officer

Uri YablonkaCTO

Executive Vice President, Chief Business Officer, Secretary & Director

Total 7 executives

BCLI Frequently asked questions

What is Brainstorm Cell Therapeutics Inc. (BCLI) Stock Price?

Current stock price of Brainstorm Cell Therapeutics Inc. (BCLI) stock is $1.250. The stock price is +5.93% higher in the session. The intraday range can be seen from this page. Volume of Brainstorm Cell Therapeutics Inc. (BCLI) stock is 19.58K.

Last updated at 02 Sept 2026, 07:59 pm.

Why is the Brainstorm Cell Therapeutics Inc. (BCLI) stock price going up or down today?

The stock price of Brainstorm Cell Therapeutics Inc. (BCLI) can change with earnings, company news, and overall market sentiment. Brainstorm Cell Therapeutics Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Brainstorm Cell Therapeutics Inc. stock expensive at its current price?

Whether Brainstorm Cell Therapeutics Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BCLI on this page is -0.77. EPS on this page is -1.63. Compare those figures with peers and growth expectations before deciding if the current Brainstorm Cell Therapeutics Inc. price is justified.

How has the stock price of Brainstorm Cell Therapeutics Inc. (BCLI) performed historically?

Historical performance for Brainstorm Cell Therapeutics Inc. (BCLI) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BCLI reacted to past earnings and market events.

Should I buy Brainstorm Cell Therapeutics Inc. (BCLI) stock, at this price?

Buying Brainstorm Cell Therapeutics Inc. (BCLI) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.